Gefitinib Exporter: Delivering Precision Medicine for Lung Cancer
Gefitinib has emerged as a significant medicine in the treatment of non-small cell lung cancer (NSCLC), providing a targeted therapeutic option with better patient results. Gefitinib, a tyrosine kinase inhibitor (TKI), targets particular mutations within the epidermal growth factor receptor (EGFR), which are frequent in NSCLC patients. This precision medicine method has transformed lung cancer…